Clinical success of the trial on key AstraZeneca ovarian cancer drug

One of the important new AstraZeneca cancer drug succeeded in clinical trials, which can lead to a significant increase in the number of women who are unable to access medication.

Phase three trials Lynparza as a first-line treatment of women with ovarian cancer have inherited genetic mutations known as gene breast cancer. This means, Lynparza was given relative only to the women after they were diagnosed and, along with the first round of chemotherapy.

At the moment, Lynparza approved for use in women with ovarian cancer at a late stage of disease progression.

Although the company has not yet released data pharmaceutical the company said that the results showed “statistically-significant and clinically meaningful” improvement in the length of time it took for the cancer to start spreading again in patients who received Lynparza, compared to those on placebo.

AstraZeneca 1-year stock price

Approx 15pcs patients with ovarian cancer have a brca genetic mutation, for this purpose Lynparza.

Lynparza is part of a new class of cancer drugs called parp inhibitors. It works by disrupting the special cell systems in the body, whose function is to repair damaged DNA in cancer tumors, without which tumors cannot grow.

“Findings highlight the importance of knowing brca, status at the time of diagnosis, and this may allow women with brca-mutated ovarian cancer receiving Lynparza to before,” said Sean site bohen, medical Director, AstraZeneca. “

AstraZeneca develops and comercializare Lynparza in partnership with the American pharmaceutical giant Merck.

Positive results could lead to 30pcs to 50pcs increase in the number of women who can access the drug, said press-Secretary of company “AstraZeneca”.

Lynparza is the most advanced parp inhibitor on the market. AstraZeneca believes that this is 18 months ahead of its competitors in terms of regulatory approval and commercialization. The drug is also available for women with breast cancer and a number of other signs.

Last year Lynparza sales of $297m (£225.5 m), 36pcs increase compared to the previous year.